A Double-Blind, Placebo-Controlled Pilot Study of Galantamine to Improve Cognitive Dysfunction in Minimally Symptomatic Bipolar Disorder

Abstract

Episodic memory performance was improved in the galantamine treatment group but did not improve in the placebo group. In contrast, performance on 2 of the processing speed measures showed significant improvement in the placebo condition, whereas that of the patients treated with galantamine did not improve. Galantamine may thus have specific benefits for episodic memory, but not processing speed, in patients with cognitive impairment as part of bipolar disorder.